1、 KANG S, XIE J, MIAO J, et al. A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response[J]. Cancer Immunol Immunother, 2013, 62(1):183-190. KANG S, XIE J, MIAO J, et al. A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response[J]. Cancer Immunol Immunother, 2013, 62(1):183-190.
2、 RZYMSKI T, MIKULA M, ZYLKIEWICZ E, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains[J]. Oncotarget,2017, 8(20):33779-33795. RZYMSKI T, MIKULA M, ZYLKIEWICZ E, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains[J]. Oncotarget,2017, 8(20):33779-33795.
3、 PELISH H E, LIAU B B, NITULESCU I I, et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML[J]. Nature,2015, 526(7572):273-276. PELISH H E, LIAU B B, NITULESCU I I, et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML[J]. Nature,2015, 526(7572):273-276.
4、 ROEMER K. NOTCH and the p53 clan of transcription factors[J]. Adv Exp Med Biol,2012(727):223-240. ROEMER K. NOTCH and the p53 clan of transcription factors[J]. Adv Exp Med Biol,2012(727):223-240.
5、 FERRANDINO F, GRAZIOLI P, BELLAVIA D, et al. NOTCH and NF-κB: Coach and players of regulatory t-cell response in cancer[J]. Front Immunol,2018(9):2165. FERRANDINO F, GRAZIOLI P, BELLAVIA D, et al. NOTCH and NF-κB: Coach and players of regulatory t-cell response in cancer[J]. Front Immunol,2018(9):2165.
6、 KIM W, KHAN S K, GVOZDENOVIC-JEREMIC J, et al. Hippo signaling interactions with Wnt/β-catenin and NOTCH signaling repress liver tumorigenesis[J]. J Clin Invest, 2017, 127(1):137-152. KIM W, KHAN S K, GVOZDENOVIC-JEREMIC J, et al. Hippo signaling interactions with Wnt/β-catenin and NOTCH signaling repress liver tumorigenesis[J]. J Clin Invest, 2017, 127(1):137-152.
7、 BOUSQUET MUR E, BERNARDO S, PAPON L, et al. NOTCH inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma[J]. J Clin Invest,2020, 130(2):612-624. BOUSQUET MUR E, BERNARDO S, PAPON L, et al. NOTCH inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma[J]. J Clin Invest,2020, 130(2):612-624.
8、 GENG Y, FAN J, CHEN L, et al. A NOTCH-dependent inflammatory feedback circuit between macrophages and cancer cells regulates pancreatic cancer metastasis[J]. Cancer Res, 2021, 81(1):64-76. GENG Y, FAN J, CHEN L, et al. A NOTCH-dependent inflammatory feedback circuit between macrophages and cancer cells regulates pancreatic cancer metastasis[J]. Cancer Res, 2021, 81(1):64-76.
9、 LIU J, SATO C, CERLETTI M, et al. NOTCH signaling in the regulation of stem cell self-renewal and differentiation[J]. Curr Top Dev Biol, 2010(92):367-409. LIU J, SATO C, CERLETTI M, et al. NOTCH signaling in the regulation of stem cell self-renewal and differentiation[J]. Curr Top Dev Biol, 2010(92):367-409.
10、 HIBDON E S, RAZUMILAVA N, KEELEY T M, et al. NOTCH and mTOR signaling pathways promote human GC cell proliferation[J]. Neoplasia,2019, 21(7):702-712. HIBDON E S, RAZUMILAVA N, KEELEY T M, et al. NOTCH and mTOR signaling pathways promote human GC cell proliferation[J]. Neoplasia,2019, 21(7):702-712.
11、 MOGHBELI M, MOSANNEN MOZAFFARI H, MEMAR B, et al. Role of MAML1 in targeted therapy against the esophageal cancer stem cells[J]. J Transl Med,2019, 17(1):126. MOGHBELI M, MOSANNEN MOZAFFARI H, MEMAR B, et al. Role of MAML1 in targeted therapy against the esophageal cancer stem cells[J]. J Transl Med,2019, 17(1):126.
12、 FORGHANIFARD M M, MOAVEN O, FARSHCHIAN M, et al. Expression analysis elucidates the roles of MAML1 and Twist1 in esophageal squamous cell carcinoma aggressiveness and metastasis[J]. Ann Surg Oncol,2012, 19(3):743-749. FORGHANIFARD M M, MOAVEN O, FARSHCHIAN M, et al. Expression analysis elucidates the roles of MAML1 and Twist1 in esophageal squamous cell carcinoma aggressiveness and metastasis[J]. Ann Surg Oncol,2012, 19(3):743-749.
13、 HASHEMI BIDOKHTI M, ABBASZADEGAN M R, SHARIFI N, et al. Contribution of MAMLI in esophageal squamous cell carcinoma tumorigenesis[J]. Ann Diagn Pathol,2017(27):79-82. HASHEMI BIDOKHTI M, ABBASZADEGAN M R, SHARIFI N, et al. Contribution of MAMLI in esophageal squamous cell carcinoma tumorigenesis[J]. Ann Diagn Pathol,2017(27):79-82.
14、 LI B, SEVERSON E, PIGNON J C, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy[J]. Genome Biology, 2016, 17(1):174. LI B, SEVERSON E, PIGNON J C, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy[J]. Genome Biology, 2016, 17(1):174.
15、 LI T, FAN J, WANG B, et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21): e108-e110. LI T, FAN J, WANG B, et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21): e108-e110.
16、 PATHAN M, KEERTHIKUMAR S, ANG C S, et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool[J]. Proteomics,2015, 15(15):2597-2601. PATHAN M, KEERTHIKUMAR S, ANG C S, et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool[J]. Proteomics,2015, 15(15):2597-2601.
17、 SZKLARCZYK D, GABLE A L, LYON D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res,2019, 47(D1): D607-D613. SZKLARCZYK D, GABLE A L, LYON D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res,2019, 47(D1): D607-D613.
18、 OOI C H, IVANOVA T, WU J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer[J]. PLoS Genet,2009, 5(10): e1000676. OOI C H, IVANOVA T, WU J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer[J]. PLoS Genet,2009, 5(10): e1000676.
19、 WANG Z, JENSEN M A, ZENKLUSEN J C. A practical guide to The Cancer Genome Atlas (TCGA)[J]. Methods Mol Biol, 2016(1418):111-141. WANG Z, JENSEN M A, ZENKLUSEN J C. A practical guide to The Cancer Genome Atlas (TCGA)[J]. Methods Mol Biol, 2016(1418):111-141.
20、 KITAGAWA M, OYAMA T, KAWASHIMA T, et al. A human protein with sequence similarity to Drosophila mastermind coordinates the nuclear form of NOTCH and a CSL protein to build a transcriptional activator complex on target promoters[J]. Mol Cell Biol, 2001, 21(13):4337-4346. KITAGAWA M, OYAMA T, KAWASHIMA T, et al. A human protein with sequence similarity to Drosophila mastermind coordinates the nuclear form of NOTCH and a CSL protein to build a transcriptional activator complex on target promoters[J]. Mol Cell Biol, 2001, 21(13):4337-4346.
21、 WU L, ASTER J C, BLAKLOW S C, et al. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors[J]. Nat Genet,2000, 26(4):484-489. WU L, ASTER J C, BLAKLOW S C, et al. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors[J]. Nat Genet,2000, 26(4):484-489.
22、 MURO K, CHUNG H C, SHANKARAN V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial[J]. Lancet Oncol,2016, 17(6):717-726. MURO K, CHUNG H C, SHANKARAN V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial[J]. Lancet Oncol,2016, 17(6):717-726.
23、 GU L, CHEN M, GUO D, et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis[J]. PLoS One,2017, 12(8): e0182692. GU L, CHEN M, GUO D, et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis[J]. PLoS One,2017, 12(8): e0182692.
24、 MONDACA S, MARGOIS M, SANCHEZ-VEGA F, et al. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer[J]. Gastric Cancer,2019, 22(2):355-362. MONDACA S, MARGOIS M, SANCHEZ-VEGA F, et al. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer[J]. Gastric Cancer,2019, 22(2):355-362.
25、 JHAVERI K L, WANG X V, MAKKER V, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q[J]. Ann Oncol, 2019, 30(11):1821-1830. JHAVERI K L, WANG X V, MAKKER V, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q[J]. Ann Oncol, 2019, 30(11):1821-1830.
26、 BOKU N. HER2-positive gastric cancer[J]. Gastric Cancer, 2014, 17(1):1-12. BOKU N. HER2-positive gastric cancer[J]. Gastric Cancer, 2014, 17(1):1-12.
27、 LEE Y C, CHIANG T H, CHOU C K, et al. Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and Meta-analysis[J]. Gastroenterology,2016, 150(5):1113-1124. LEE Y C, CHIANG T H, CHOU C K, et al. Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and Meta-analysis[J]. Gastroenterology,2016, 150(5):1113-1124.
28、 GUO Y, ZHANG Y, GERHARD M, et al. Effect of helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer[J]. Gut,2020, 69(9):1598-1607. GUO Y, ZHANG Y, GERHARD M, et al. Effect of helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer[J]. Gut,2020, 69(9):1598-1607.
